United Gene High-Tech (HKG:0399) announced that it has entered into an agreement with Extrawell Pharmaceutical (HKG:0858) for Extrawell to inject RMB2.5 million (HK$3.08 million) cash as 20% of registered capital of Longmark (Shanghai) HealthCare Limited as enlarged after such injection of capital.

Upon the completion of the injection, the enlarged registered capital of Longmark will be owned as to 20% by Extrawell and 80% by United Gene High-Tech. The injection is subject to the approval of the respective governmental bodies of PRC.

Longmark is principally engaged in business of the provision of health-care management services.